# Evaluation of the Effect of ATX-101 on QT/QTc Intervals

> **NCT01706679** · PHASE1 · COMPLETED · sponsor: **Kythera Biopharmaceuticals** · enrollment: 218 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ATX-101 (10 mg/ml)
- **DRUG:** ATX-101 (20 mg/ml)
- **DRUG:** Moxifloxacin (400 mg)
- **DRUG:** Placebo vehicle (PBS)

## Key facts

- **NCT ID:** NCT01706679
- **Lead sponsor:** Kythera Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-02
- **Final completion:** 2013-06
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2013-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706679, "Evaluation of the Effect of ATX-101 on QT/QTc Intervals". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01706679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*